TỔNG QUAN BỆNH LÍ LIÊN QUAN IgG4
##plugins.themes.vojs.article.main##
Abstract
IgG4-related disease (IgG4-RD) is a newly recognized disorder that is an immune-mediated fibroinflammatory condition. Main features of the disease include: Lesions in various organs, dense lymphocytic infiltrates with many IgG4-positive plasma cells, chain fibrosis and often high serum IgG4 levels. It may be confused with cancer, immune-mediated disease, or infection. Diagnosis is based on a combination of clinical features, test results and histopathology results, in which histopathology is the golden standard with IgG4+/IgG+ ratio >40%. If left untreated, IgG4-RD can cause irreversible organ disease, so early and aggressive treatment is needed. Glucocorticoids are the first choice of treatment for adults, with prednisone at a dose of 0.5 -1 mg/kg/day, and are also the first choice for IgG4-RD in children. There is no consensus on prednisone dosage in pediatrics, but in general prednisone 1 to 2 mg/kg/day is appropriate. Combining corticosteroids and immunosuppress has been shown to increase the chance of response and reduce the risk of disease recurrence. Biological drugs are considered a potential treatment trend in the future.
##plugins.themes.vojs.article.details##
References
2. Floreani A, Okazaki K, Uchida K et al. IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease. J Transl Autoimmun 2021;4:100074. http://dx.doi.org/10.1016/j.jtauto.2020.100074
3. Karim F, Loeffen J, Bramer W et al. IgG4-related disease: a systematic review of this unrecognized disease in pediatrics. Pediatric Rheumatology 2016;14(1):18. https://doi.org/10.1186/s12969-016-0079-3
4. Karadeniz H, Vaglio A. IgG4-related disease: a contemporary review. Turk J Med Sci 2020;50(7):1616-1631. https://doi.org/10.3906/sag-2006-375
5. Maehara T, Moriyama M, Nakamura S. Pathogenesis of IgG4-related disease: a critical review. Odontology 2019;107(2):127-132. https://doi.org/10.1007/s10266-018-0377-y
6. Wallace ZS, Zhang Y, Perugino CA et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 2019;78(3):406-412. https://doi.org/10.1136/annrheumdis-2018-214603
7. Zhang W, Stone J. Management of IgG4-related disease. The Lancet Rheumatology 2019;1:e55-e65. https://doi.org/10.1016/S2665-9913(19)30017-7
8. Nares EM, Prieto TD, Faugier-Fuentes E et al. Juvenile-Onset IgG4-Related Disease: A Systematic Review. ACR Meeting Abstracts 2019;(1709).
9. Wallace ZS, Naden RP, Chari S et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis & Rheumatology 2020;72(1):7-19. https://doi.org/10.1002/art.41120
10. Umehara H, Okazaki K, Kawa S et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 2021;31(3):529-533. https://doi.org/10.1080/14397595.2020.1859710
11. Stone JH, Zen Y, Deshpande V. IgG4-Related Disease. New England Journal of Medicine 2012;366(6):539-551. https://doi.org/10.1056/NEJMra1104650
12. Wallace ZS, Katz G, Hernandez-Barco YG et al. Current and future advances in practice: IgG4-related disease. Rheumatology Advances in Practice 2024;8(2):rkae020. https://doi.org/10.1093/rap/rkae020
13. Khosroshahi A, Wallace ZS, Crowe JL. International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease. Arthritis Rheumatol 2015;67(7):1688-1699. https://doi.org/10.1002/art.39132
14. Hegade VS, Sheridan MB, Huggett MT. Diagnosis and management of IgG4-related disease. Frontline Gastroenterol 2019;10(3):275-283. https://doi.org/10.1136/flgastro-2018-101001
15. Tanaka Y, Stone JH. Perspectives on current and emerging therapies for immunoglobulin G4–related disease. Mod Rheumatol 2023;33(2):229-236. https://doi.org/10.1093/mr/roac141